(Q24244978)

2

0 references

G Haddour

3

0 references

Jean-Pierre Boissel

4

0 references

Patrice Nony

Cochrane Database of Systematic Reviews

5

0 references

publication date

24 January 2005

0 references

published in

0 references

cites work

Treatment of severe heart failure: quantity or quality of life? A trial of enoximone. Enoximone Investigators

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure study (EPOCH study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death. PROMISE (Prospective Randomized Milrinone Survival Evaluation) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

Comparison of the effects of captopril and enoximone in patients with severe heart failure: a placebo controlled double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

Exercise tolerance in patients with heart failure--how should it be measured?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

Effect of flosequinan on exercise capacity and symptoms in severe heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

The effects of flosequinan on submaximal exercise in patients with chronic cardiac failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

Effect of flosequinan on exercise capacity and cardiac function in patients with chronic mild heart failure: a double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

Placebo-controlled study of oral enoximone in congestive heart failure with initial and final intravenous hemodynamic evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

Withdrawal of long-term amrinone therapy in patients with congestive heart failure: a placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

Relation of circulating cardiac myosin light chain 1 isoform in stable severe congestive heart failure to survival and treatment with flosequinan

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

ACE inhibitors--a cornerstone of the treatment of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

Vasodilator therapy of cardiac failure (second of two parts).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

Cardiovascular effects of milrinone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

Acute positive inotropic intervention: the phosphodiesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

Effect of drug therapy on survival in chronic congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

A note on graphical presentation of estimated odds ratios from several clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

Controlled and uncontrolled studies of phosphodiesterase III inhibitors in contemporary cardiovascular medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

Cardiomyopathy of overload. A major determinant of prognosis in congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

Sustained beneficial effects of oral amrinone on cardiac and renal function in patients with severe congestive heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

Intravenous use of amrinone for the treatment of the failing heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

Relative efficacy of vasodilator therapy in chronic congestive heart failure. Implications of randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

Standardization of terminology in meta-analysis: a proposal for working definitions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

Effect of vasodilator and inotropic drugs on clinical symptoms and long-term survival in chronic congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

Vasodilator and inotropic drugs for the treatment of chronic heart failure: distinguishing hype from hope

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

Effect of carvedilol on survival in severe chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

The file drawer problem and tolerance for null results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

Milrinone in congestive heart failure: acute and chronic hemodynamic and clinical evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

Non-receptor-mediated inotropic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

Some Thoughts on Clinical Trials, Especially Problems of Multiplicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

Newer positive inotropic agents in the treatment of chronic cardiac failure. Current status and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

Inotropic and vasodilator effects of amrinone on isolated human tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

Flosequinan in chronic heart failure: how is exercise capacity improved?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

Chronic vasodilator therapy with flosequinan in congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

7 January 2021

Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients. A meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

7 January 2021

A placebo-controlled, randomized, double-blind study of OPC-8212 in patients with mild chronic heart failure. OPC-8212 Multicenter Research Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

7 January 2021

Milrinone in the treatment of chronic cardiac failure: a controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

7 January 2021

Central and regional hemodynamic effects of oral enoximone in congestive heart failure: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

7 January 2021

Disparity between improvement in left ventricular function and changes in clinical status and exercise capacity during chronic enoximone therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

7 January 2021

A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

7 January 2021

Influence of flosequinan on autonomic tone in congestive heart failure: implications for the mechanism of the positive chronotropic effect and survival influence of long-term vasodilator administration

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

7 January 2021

A double-blind dose response comparison of oral enoximone and placebo for congestive heart failure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

7 January 2021

Usefulness of OPC-8212, a quinolinone derivative, for chronic congestive heart failure in patients with ischemic heart disease or idiopathic dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

7 January 2021

Effectiveness of imazodan for treatment of chronic congestive heart failure. The Imazodan Research Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

7 January 2021

Placebo-controlled trial of oral enoximone in end-stage congestive heart failure refractory to optimal treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

7 January 2021

Placebo-controlled trial of flosequinan in moderate heart failure. The possible importance of aetiology and method of analysis in the interpretation of the results of heart failure trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

7 January 2021

Considerations for the meta-analysis of randomized clinical trials. Summary of a panel discussion

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

7 January 2021

[Introduction to meta-analytic methodology]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

7 January 2021

Clinical and prognostic significance of serum magnesium concentration in patients with severe chronic congestive heart failure: the PROMISE Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

7 January 2021

Efficacy of phosphodiesterase inhibition with milrinone in combination with converting enzyme inhibitors in patients with heart failure. The Milrinone Multicenter Trials Investigators

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

7 January 2021

Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

7 January 2021

Neurohormonal activation in severe heart failure: relations to patient death and the effect of treatment with flosequinan

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

7 January 2021

Effectiveness of carvedilol alone versus carvedilol + pimobendan for severe congestive heart failure. For the Keio Interhospital Cardiology Study (KICS) Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

7 January 2021

Low-dose enoximone improves exercise capacity in chronic heart failure. Enoximone Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

7 January 2021

Oral amrinone for the treatment of chronic congestive heart failure: results of a multicenter randomized double-blind and placebo-controlled withdrawal study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

7 January 2021

Implication of evidence-based medicine in prescription guidelines taught to French medical students: current status in the cardiovascular field

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

7 January 2021

A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

7 January 2021

Inotropic therapy for heart failure--an unfulfilled promise

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

7 January 2021

Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

7 January 2021

Vasodilator therapy for chronic heart failure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

7 January 2021

Vasodilator therapy for heart failure. The influence of impedance on left ventricular performance

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

7 January 2021

Comparative hemodynamic effects of inotropic and vasodilator drugs in severe heart failure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

7 January 2021

Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

7 January 2021

Separation of the direct myocardial and vasodilator actions of milrinone administered by an intracoronary infusion technique

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

7 January 2021

Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

7 January 2021

Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

7 January 2021

Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

7 January 2021

The Combination of Estimates from Different Experiments

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002230.PUB2

7 January 2021

10.1002/14651858.CD002230.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

4110681

4110681

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference